Skip to content
value.today
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc.

ARMP
$130 Mmarket cap on Oct 28, 2026+11.9% since Jan 2024
Compare
World rank
#17,794
Revenue
—
For year ending December-2025
Net income
$-174 M
SEC filing
Employees
61
As of March 18, 2026
SEC filing

Armata Pharmaceuticals, Inc. in brief

Armata Pharmaceuticals, Inc. is a listed company in the Biotechnology industry, based in Los Angeles, California, USA. Its market value was $130 M on 28 October 2026, which makes it the 17,794th largest listed company in the world and the 3,382nd largest in the USA on this site. It employs about 61 people and Deborah Birx is its chief executive. Its shares trade under the symbol ARMP (NYSE).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Armata Pharmaceuticals, Inc.

We are a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using our proprietary bacteriophage-based technology. We have completed three Phase 2 clinical trials to date.

We see bacteriophages as a potentially safer and effective alternative to antibiotics and an essential response to the growing bacterial resistance to current classes of antibiotics. Bacteriophages or “phages” have a powerful and highly differentiated mechanism of action that enables binding to and killing of specific targeted bacteria while uniquely preserving the normal human microbiome or “healthy bacteria”. This is in direct contrast to traditional broad-spectrum antibiotics which can alter the human microbiome increasing susceptibility to opportunistic pathogens, such as Clostridium difficile. We believe that phages represent a promising means to effectively treat bacterial infections as an alternative to broad-spectrum antibiotics, especially for patients with bacterial infections resistant to current standard of care therapies, including the multidrug-resistant or “superbug” strains of bacteria. We are a leading developer of clinical-stage phage therapeutics of high purity and potency, and believe we are uniquely positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections.

From the company's annual report filed with the US SEC: read the report

Armata Pharmaceuticals, Inc. timeline

3 events, 1996–2019
  1. 1996
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2011
  4. ✎
    Renamed AmpliPhi Biosciences Corp
    Formerly Targeted Genetics Corp /Wa/.
  5. 2019
  6. ✎
    Renamed Armata Pharmaceuticals, Inc.
    Formerly AmpliPhi Biosciences Corp.

Events of Armata Pharmaceuticals, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$104 M$208 M$313 M$417 M2020202120222023202420252026

World rank over time

▲ up 5,708 places since 2020
2020-01-01: #23544#23,54420202021-01-01: #20296#20,29620212022-01-07: #20434#20,43420222022-12-25: #25520#25,52020222023-07-30: #22363#22,36320232024-01-05: #20647#20,64720242026-03-08: #7773#7,77320262026-08-01: #15881#15,88120262026-10-08: #17568#17,56820262026-10-28: #17836#17,8362026

Rank in USA: #4,314 (Jan 2020) · #4,000 (Jan 2021) · #4,029 (Jan 2022) · #4,836 (Dec 2022) · #4,332 (Jul 2023) · #3,599 (Jan 2024) · #1,380 (Mar 2026) · #3,178 (Aug 2026) · #3,313 (Oct 2026) · #3,386 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
-20.3%
Net margin
—
Operating margin
—
Return on equity
—
Liabilities / assets
384.3%
Revenue growth
+412.5%
R&D / revenue
1414.6%
Profit per employee
$-2.8 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-17M—FY18Fiscal year ending Dec 2019: revenue —, net income $-19M—FY19Fiscal year ending Dec 2020: revenue —, net income $-22M—FY20Fiscal year ending Dec 2021: revenue —, net income $-23M—FY21Fiscal year ending Dec 2022: revenue —, net income $-37M—FY22Fiscal year ending Dec 2023: revenue —, net income $-69M—FY23Fiscal year ending Dec 2024: revenue —, net income $-19M—FY24Fiscal year ending Dec 2025: revenue —, net income $-174M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-37M$-174M—
Dec 2024——$-42M$-19M—
Dec 2023——$-41M$-69M—
Dec 2022——$-37M$-37M—
Dec 2021——$-24M$-23M—
Dec 2020——$-22M$-22M—
Dec 2019——$-20M$-19M—
Dec 2018——$-18M$-17M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-26M$1M$-26M$-4.80—
Dec 2024$-38M$2M$-39M$-0.89—
Dec 2023$-47M$8M$-56M$-1.91—
Dec 2022$-32M$2M$-35M$-1.08—
Dec 2021$-24M$1M$-25M$-0.96—
Dec 2020$-18M$1M$-19M$-1.35—
Dec 2019$-16M$0M$-16M$-2.55—
Dec 2018$-11M$1M$-12M$-3.59—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $3M—Dec ’24Three months to Mar 2025: revenue —, net income $-7M—Mar ’25Three months to Jun 2025: revenue —, net income $-16M—Jun ’25Three months to Sep 2025: revenue —, net income $-27M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-124M—Dec ’25Three months to Mar 2026: revenue —, net income $-115M—Mar ’26Three months to Jun 2026: revenue —, net income $74M—Jun ’26Three months to Sep 2026: revenue —, net income $55M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $55M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Armata Pharmaceuticals, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-37 M
Net income
$-174 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$77 M
Total liabilities
$295 M
Total equity
$-219 M

As of December-2025

Top 64 institutional investors in Armata Pharmaceuticals, Inc.#

As of Sep 30, 2026
64 institutions held 5.6 M shares (about 15.2% of the shares outstanding) on Sep 30, 2026. The ten largest hold 13.5%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Armata Pharmaceuticals, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Madison Asset Management, LLC2,107,1750 (0.00%)5.67%$8 MNov 12, 2026
2Millennium Management LLC1,054,231+583,731 (+124.07%)2.83%$4 MNov 16, 2026
3BlackRock, Inc.558,226-1,760 (-0.31%)1.50%$2 MNov 13, 2026
4Vanguard Capital Management LLC487,9680 (0.00%)1.31%$2 MNov 13, 2026
5Geode Capital Management, LLC278,544+7,994 (+2.95%)0.75%$1 MNov 6, 2026
6State Street Corp184,501+54,901 (+42.36%)0.50%$1 MNov 12, 2026
7Grey Ledge Advisors, LLC100,000+50,000 (+100.00%)0.27%$0 MNov 2, 2026
8Northern Trust Corp90,571+780 (+0.87%)0.24%$0 MNov 16, 2026
9Vanguard Portfolio Management LLC81,579+225 (+0.28%)0.22%$0 MNov 13, 2026
10Edgewood Management LLC80,0000 (0.00%)0.22%$0 MNov 12, 2026
11Vanguard Fiduciary Trust Co79,385-110 (-0.14%)0.21%$0 MNov 13, 2026
12UBS Group AG54,374+40,677 (+296.98%)0.15%$0 MNov 10, 2026
13Bridgeway Capital Management, LLC43,988-694 (-1.55%)0.12%$0 MNov 16, 2026
14SeaCrest Wealth Management, LLC41,899+375 (+0.90%)0.11%$0 MOct 21, 2026
15Empowered Funds, LLC40,688New0.11%$0 MNov 13, 2026
16Renaissance Technologies LLC34,653-13,665 (-28.28%)0.09%$0 MNov 12, 2026
17Bank of New York Mellon Corp30,559+810 (+2.72%)0.08%$0 MNov 5, 2026
18Charles Schwab Investment Management Inc28,863+6 (+0.02%)0.08%$0 MNov 16, 2026
19XTX Topco Ltd27,867+17,041 (+157.41%)0.07%$0 MNov 16, 2026
20Goldman Sachs Group Inc25,156New0.07%$0 MNov 16, 2026
21Hudson Bay Capital Management LP17,5840 (0.00%)0.05%$0 MNov 13, 2026
22Nuveen, LLC17,545+1,640 (+10.31%)0.05%$0 MNov 10, 2026
23Susquehanna International Group, LLP15,913New0.04%$0 MNov 16, 2026
24New York State Common Retirement Fund15,4000 (0.00%)0.04%$0 MNov 17, 2026
25Price T Rowe Associates Inc /MD/15,330New0.04%$0 MNov 16, 2026
Show all 64: investors 26 to 64
Institutional investors 26 to 64 in Armata Pharmaceuticals, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Bank Of America Corp /de/14,484+3,179 (+28.12%)0.04%$0 MNov 16, 2026
27Nisa Investment Advisors, LLC13,650New0.04%$0 MOct 20, 2026
28Captrust Financial Advisors13,238+98 (+0.75%)0.04%$0 MNov 12, 2026
29Deutsche Bank AG\11,593-373 (-3.12%)0.03%$0 MNov 6, 2026
30Dauntless Investment Group, LLC9,105-194,786 (-95.53%)0.02%$0 MNov 16, 2026
31Rhumbline Advisers8,177-276 (-3.27%)0.02%$0 MNov 10, 2026
32Police & Firemen's Retirement System of New Jersey6,0950 (0.00%)0.02%$0 MNov 9, 2026
33MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.5,729+268 (+4.91%)0.02%$0 MNov 16, 2026
34Jpmorgan Chase & Co5,617+701 (+14.26%)0.02%$0 MNov 12, 2026
35Morgan Stanley5,412+829 (+18.09%)0.01%$0 MNov 13, 2026
36Barclays PLC5,122+2,138 (+71.65%)0.01%$0 MNov 6, 2026
37Russell Investments Group, Ltd.4,503+3,534 (+364.71%)0.01%$0 MNov 6, 2026
38Vanguard Global Advisers, LLC4,022+58 (+1.46%)0.01%$0 MNov 13, 2026
39Wells Fargo & Company/mn3,605-7,214 (-66.68%)0.01%$0 MNov 16, 2026
40BNP Paribas Financial Markets3,579+541 (+17.81%)0.01%$0 MNov 12, 2026
41Royal Bank Of Canada2,753+2,256 (+453.92%)0.01%$0 MNov 16, 2026
42Tower Research Capital LLC (TRC)2,524+490 (+24.09%)0.01%$0 MNov 16, 2026
43Cornerstone National Bank & Trust Co1,4280 (0.00%)0.00%$0 MOct 20, 2026
44FMR LLC1,415+1,051 (+288.74%)0.00%$0 MNov 10, 2026
45Legal & General Group Plc1,1610 (0.00%)0.00%$0 MNov 16, 2026
46Ameritas Investment Partners, Inc.1,0760 (0.00%)0.00%$0 MNov 13, 2026
47Measured Wealth Private Client Group, LLC1,0000 (0.00%)0.00%$0 MNov 10, 2026
48Trifecta Capital Advisors, LLC7140 (0.00%)0.00%$0 MOct 21, 2026
49Farther Finance Advisors, LLC597New0.00%$0 MOct 8, 2026
50Citigroup Inc589-5,014 (-89.49%)0.00%$0 MNov 4, 2026
51Northwestern Mutual Wealth Management Co5710 (0.00%)0.00%$0 MNov 13, 2026
52GAMMA Investing LLC550New0.00%$0 MOct 8, 2026
53Sterling Capital Management LLC389+347 (+826.19%)0.00%$0 MOct 22, 2026
54Caitong International Asset Management Co., Ltd219New0.00%$0 MOct 29, 2026
55Silver Grove Financial Group, Inc.2000 (0.00%)0.00%$0 MNov 5, 2026
56Simplex Trading, LLC183-611 (-76.95%)0.00%$0 MNov 4, 2026
57Arax Advisory Partners138New0.00%$0 MNov 12, 2026
58Whittier Trust Co1000 (0.00%)0.00%$0 MNov 12, 2026
59North Star Investment Management Corp.99New0.00%$0 MOct 27, 2026
60Team Financial Group, LLC71New0.00%$0 MOct 30, 2026
61EverSource Wealth Advisors, LLC13New0.00%$0 MNov 4, 2026
62SBI Securities Co., Ltd.30 (0.00%)0.00%$0 MOct 22, 2026
63Allworth Financial LP1New0.00%$0 MNov 17, 2026
64IFP Advisors, Inc1New0.00%$0 MOct 16, 2026

Mutual funds holding Armata Pharmaceuticals, Inc.#

39 funds hold shares worth $8 M (about 3.3% of the company). Since their previous reports 34 added shares and 1 sold, buying $4 M net.
Mutual funds holding Armata Pharmaceuticals, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.349,598$2 M0.94%<0.01%+47%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors197,072$1 M0.53%<0.01%newJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.125,873$1 M0.34%<0.01%+11%Jun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors111,368$1 M0.30%<0.01%newJun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC128,856$1 M0.35%<0.01%newJul 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC56,701$0 M0.15%<0.01%−2.7%May 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC41,382$0 M0.11%0.18%no changeJun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors39,743$0 M0.11%0.02%+47%Jun 30, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC22,168$0 M0.06%<0.01%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC17,296$0 M0.05%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC16,271$0 M0.04%<0.01%+11%May 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.28,857$0 M0.08%<0.01%newJul 31, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC11,252$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC11,164$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC15,905$0 M0.04%<0.01%newJul 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation9,700$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.7,181$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.6,700$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.6,118$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.5,316$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC5,649$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC3,826$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC3,267$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC2,628$0 M<0.01%<0.01%+33%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS2,478$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.1,840$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC1,796$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC1,703$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management1,076$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC1,044$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC969$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC1,389$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.1,328$0 M<0.01%<0.01%+5.1%Jul 31, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC830$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC830$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS1,178$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC779$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC907$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.406$0 M<0.01%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 39 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Armata Pharmaceuticals, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
16
since
Armata Pharmaceuticals, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Deborah BirxChief Executive Officer, DirectorShares withheld for tax-14,041$4.260$60 K198,417Form 4
filed Pierre KymeChief Business OfficerShares withheld for tax-1,030$10.54$11 K9,461Form 4
filed Deborah BirxChief Executive Officer, DirectorShares withheld for tax-4,919$10.54$52 K212,458Form 4
filed Deborah BirxChief Executive Officer, DirectorShares withheld for tax-13,637$2.270$31 K217,377Form 4
filed Pierre KymeChief Business OfficerShares withheld for tax-1,027$1.950$2 K10,491Form 4
filed Deborah BirxChief Executive Officer, DirectorShares withheld for tax-6,061$1.950$12 K231,014Form 4
filed Deborah BirxChief Executive Officer, DirectorShares withheld for tax-22,925$2.680$61 K237,075Form 4
filed Deborah BirxChief Executive Officer, DirectorGrant or award+60,000——260,000Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Armata Pharmaceuticals, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
912,610
2.5% of shares · 9.78 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-14.01 reverse split in the period to ; 1-for-14.01 reverse split ; 10-for-1 split ; 50-for-1 split

Trading halts

  • 2025-11-10 15:11 UTC, code M, resumed 15:16 UTC
  • 2025-11-10 15:05 UTC, code M, resumed 15:10 UTC
  • 2025-10-22 18:23 UTC, code M, resumed 18:28 UTC
  • 2025-10-22 18:17 UTC, code M, resumed 18:22 UTC
  • 2025-10-22 18:08 UTC, code M, resumed 18:13 UTC

Fails to deliver

  • : 1,464 shares at $3.49
  • : 1,460 shares at $3.81
  • : 4,316 shares at $3.31
  • : 2,905 shares at $3.67
  • : 2,318 shares at $3.59

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Armata Pharmaceuticals, Inc. scorecard#

Passes 2 of the 11 checks that could be worked out. Fiscal year 2025; market cap of Oct 28, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-20.3%Free cash flow is -20.3% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-4.80 vs -0.89Diluted EPS -4.80 in fiscal 2025 against -0.89 the year before (report's currency).
    • ✗Net income higher than five years earlier-$174 M-$174 M in fiscal 2025 against -$22 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$174 MNet income -$174 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities1.2×Current ratio 1.19 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year-38.6%Diluted shares down 38.6% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Armata Pharmaceuticals, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Armata Pharmaceuticals, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Research and development2434343520149.88.4r2.95.7
General and administrative1213127.48.38.09.32.5r7.68.4
Operating expenses4248454228222018r1624
Operating income−37−42−41−37−24−22−20−18r−16−23
Interest and finance income——0.20.00.00.00.10.2——
Interest expense and finance costs——2.600.10.60.91.0—0.0
Other non-operating income (expense)−13724−280.00.7−0.60.31.0r2.04.0
Income before tax−174−19−69r−0.0r−23−22−19−17r−14−19
Income tax———————−0.3−1.3−0.6
Net income including minority interests−174−19−69−37−23−22−19−17——
Net income attributable to shareholders−174−19−69−37−23−22−19−17r−13−19
Earnings per share, basic-4.80-0.52-1.91-1.08-0.96-1.35-2.49-3.59r-2.01-24.67r
Earnings per share, diluted-4.80-0.89-1.91-1.08-0.96-1.35-2.55-3.59r-2.18-24.67r
Shares, weighted average (basic)3636363424167.84.7r6.41.0
Shares, weighted average (diluted)3659363424168.04.7r6.61.0r
Balance sheet
Cash and cash equivalents8.79.31415109.66.09.7r5.15.1r
Receivables—————————0.0r
Other current assets0.50.73.48.5r1.70.60.60.7r0.30.6r
Current assets1111192715116.710r5.46.3r
Property, plant and equipment1213133.62.22.02.23.2r0.81.1
Right-of-use (leased) assets3442454336112.0———
Goodwill3.53.53.53.53.53.53.5———
Other intangible assets101010101010102.74.710
Total assets7786989670402515r1118r
Accounts payable0.90.81.61.7r1.1r1.0r0.5r0.4r0.61.1r
Current liabilities8.94816254.86.74.92.0r2.03.5r
Lease liabilities (non-current)2728293236111.6———
Total liabilities295134130604421116.9r3.48.4r
Retained earnings−502−328−309−240−203−180−158−138r−394−381
Shareholders' equity−219−48−32362519157.7r24r9.7
Total liabilities and equity7786989670402515r1118r
Shares outstanding3636363627199.95.1r9.51.6r
Cash-flow statement
Depreciation and amortization—1.31.00.9——————
Share-based compensation2.62.90.93.12.93.54.30.0r0.72.0
Cash from operating activities−26−38−47−32−24−18−16−11r−9.2−11r
Capital expenditure−0.5−1.9−8.1−2.2−1.3−0.8−0.2−0.9r−0.1−0.3
Cash from investing activities−0.5−1.9−8.1−2.2−1.3−0.82.98.8r−0.1−0.3
Shares issued———44262310.0———
Dividends paid—————————−0.1
Cash from financing activities2635544426239.0128.77.2r
Change in cash−0.7−4.5−1.69.30.64.1−3.7−1.8r−0.6−3.7
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Armata Pharmaceuticals, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.2 M
Dr. Birx
Other top executives, average
$673 K
the CEO earned 1.9× this
$100 invested is now
$113
Armata Pharmaceuticals, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Dr. Birx$1.2 M$4.2 M$673 K$113
2024Deborah Birx$1.8 M$1.0 M$636 K$33
2023Deborah Birx$1.1 M$1.4 M$316 K$58

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Armata Pharmaceuticals, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 3 · Material agreement 4 · New debt 2 · Shareholder vote 2 · Results announced 8

Armata Pharmaceuticals, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K/A
Shareholder vote8-K
Material agreementNew debtResults announced8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K
Material agreement8-K
Results announced8-K
Material agreementNew debtResults announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

3 private funding rounds before listing

Private share sales · funding history

Private share sales of Armata Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2015$13 MNo. 3$10 to $50 million21equity, optionsSEC
Dec 2013$18 MNo. 2$10 to $50 million26equitySEC
Jun 2013$13 MNo. 1$10 to $50 million27equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Armata Pharmaceuticals, Inc. compares in Biotechnology

  • Market cap$130 M · higher than 40% of 726
  • Revenue growth412.5% · higher than 94% of 438
  • FCF yield-20.3% · higher than 44% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Armata Pharmaceuticals, Inc.🇺🇸$130 M——+412.5%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 28, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of March 18, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Armata Pharmaceuticals, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Armata Pharmaceuticals, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Armata Pharmaceuticals, Inc.? Suggest a correction